{"id":35510,"date":"2026-06-23T17:27:06","date_gmt":"2026-06-23T11:57:06","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=35510"},"modified":"2026-06-23T17:27:07","modified_gmt":"2026-06-23T11:57:07","slug":"pharma-news-for-definium-abbvie-apogee","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee","title":{"rendered":"Definium Reports Positive Phase 3 EMERGE Results for DT120 ODT in MDD; AbbVie to Buy Apogee Therapeutics; TrueLab Announces Strategic Antibody Licensing Collaboration with Bionyra Pharma; Nura Bio Secures Series B Financing to Advance SARM1 Programs; Moderna&#8217;s mRNA-1010 Earns Unanimous FDA Advisory Committee Backing on Benefit-Risk Profile"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a3a9c499153e\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a3a9c499153e\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee\/#Definium_Therapeutics_Advances_DT120_ODT_with_Positive_Results_from_Pivotal_Phase_3_EMERGE_Study\" >Definium Therapeutics Advances DT120 ODT with Positive Results from Pivotal Phase 3 EMERGE Study<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee\/#AbbVie_Deepens_Immunology_Capabilities_with_Apogee_Therapeutics_Acquisition\" >AbbVie Deepens Immunology Capabilities with Apogee Therapeutics Acquisition<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee\/#TrueLab_and_Bionyra_Enter_Strategic_Licensing_Agreement_for_Monoclonal_and_Bispecific_Antibody_Assets\" >TrueLab and Bionyra Enter Strategic Licensing Agreement for Monoclonal and Bispecific Antibody Assets<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee\/#Nura_Bio_Secures_738M_Series_B_to_Accelerate_SARM1_Inhibitor_Development\" >Nura Bio Secures $73.8M Series B to Accelerate SARM1 Inhibitor Development<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee\/#Modernas_mRNA-1010_Wins_Unanimous_FDA_Advisory_Committee_Support\" >Moderna&#8217;s mRNA-1010 Wins Unanimous FDA Advisory Committee Support<\/a><\/li><\/ul><\/nav><\/div>\n\n<h2 class=\"wp-block-heading\" id=\"h-definium-therapeutics-advances-dt120-odt-with-positive-results-from-pivotal-phase-3-emerge-study\"><span class=\"ez-toc-section\" id=\"Definium_Therapeutics_Advances_DT120_ODT_with_Positive_Results_from_Pivotal_Phase_3_EMERGE_Study\"><\/span>Definium Therapeutics Advances DT120 ODT with Positive Results from Pivotal Phase 3 EMERGE Study<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Definium Therapeutics, Inc. <\/strong>reported positive topline findings from Emerge, its first Phase 3 randomized, double-blind, placebo-controlled trial assessing a single 100 \u00b5g dose of <strong>DT120 (lysergide)<\/strong> orally disintegrating tablet (ODT) in <a href=\"https:\/\/www.delveinsight.com\/report-store\/major-depressive-disorder-market\">adults with major depressive disorder (MDD)<\/a>.<\/p>\n\n\n\n<p>The study successfully achieved its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in depressive symptoms versus placebo, as measured by the change from baseline in the Montgomery-\u00c5sberg Depression Rating Scale (MADRS) total score at Week 6. Patients treated with DT120 ODT 100 \u00b5g experienced a Least Squares (LS) mean reduction of 13.3 points in MADRS score from baseline, compared with a 5.2-point reduction in the placebo arm, resulting in an LS mean difference of 8.1 points in favor of DT120 (p&lt;0.0001).<\/p>\n\n\n\n<p>In addition to meeting the primary endpoint, DT120 showed a rapid onset of action, with a placebo-adjusted LS mean reduction in MADRS score of 14.2 points observed as early as Week 1 (p&lt;0.0001). The antidepressant effect also remained durable, with a placebo-adjusted LS mean reduction of 7.3 points maintained through Week 12 (p&lt;0.0001).<\/p>\n\n\n\n<p><em>&#8220;The topline results from Emerge demonstrate a highly differentiated efficacy profile, showing that a single dose of DT120 ODT can provide rapid, substantial, and sustained symptom relief for patients with MDD,&#8221; said Rob Barrow, Chief Executive Officer of Definium Therapeutics. &#8220;As the first Phase 3 study in our development program to report results, Emerge represents a significant milestone and reinforces our confidence in DT120 as a potential best-in-class therapy for mental health conditions. These findings may pave the way for a novel treatment paradigm for MDD, addressing important unmet needs among patients and healthcare providers. We thank the patients and investigators whose participation made this study possible. Supported by decades of scientific research, these results bring us closer to a potential FDA submission and the opportunity to introduce a transformative treatment option.&#8221;<\/em><\/p>\n\n\n\n<p>DT120 ODT demonstrated a favorable safety and tolerability profile. Approximately 99% of treatment-emergent adverse events were mild to moderate in severity, temporary in nature, and occurred primarily on the dosing day. No new safety concerns were identified, including no increased incidence of suicidal ideation or behavior. Treatment discontinuation rates were low and comparable between the DT120 and placebo groups.<\/p>\n\n\n\n<p>Participants underwent hourly assessments between five and eight hours after dosing using a structured End of Session Checklist (EoSC). In Part A of the study, the average time required to meet EoSC criteria among DT120-treated participants was 5.8 hours, with a median time of 5.1 hours. All participants receiving DT120 satisfied the EoSC criteria within eight hours of dosing.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-abbvie-deepens-immunology-capabilities-with-apogee-therapeutics-acquisition\"><span class=\"ez-toc-section\" id=\"AbbVie_Deepens_Immunology_Capabilities_with_Apogee_Therapeutics_Acquisition\"><\/span>AbbVie Deepens Immunology Capabilities with Apogee Therapeutics Acquisition<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>AbbVie and Apogee Therapeutics<\/strong> have entered into a definitive agreement under which AbbVie will acquire Apogee and its portfolio of clinical-stage candidates targeting inflammatory and immunological disorders, including atopic dermatitis and asthma. The transaction is intended to strengthen AbbVie\u2019s immunology franchise and expand its footprint in respiratory diseases.<\/p>\n\n\n\n<p>According to the agreement, AbbVie will purchase all outstanding Apogee shares for <strong>$135.11 per share<\/strong> in cash, valuing the company at approximately <strong>$10.9 billion<\/strong> in total equity. The boards of both companies have unanimously approved the deal, which is anticipated to close in the third quarter of 2026, subject to customary closing requirements, including shareholder and regulatory approvals.<\/p>\n\n\n\n<p><em>Commenting on the acquisition, Robert A. Michael stated that AbbVie has spent more than 20 years advancing the field of immunology and believes the addition of Apogee\u2019s pipeline will further reinforce its leadership position. He noted that the transaction broadens AbbVie\u2019s portfolio with differentiated clinical-stage assets addressing significant unmet needs in conditions such as atopic dermatitis and asthma, while leveraging AbbVie\u2019s scientific and development capabilities to accelerate these programs and improve treatment standards for patients with inflammatory diseases.<\/em><\/p>\n\n\n\n<p>The acquisition is expected to offer meaningful long-term value creation opportunities, supported by the blockbuster potential of Apogee\u2019s pipeline. Key assets include zumilokibart (APG777), a subcutaneously administered, half-life\u2013extended anti-IL-13 monoclonal antibody being developed for <a href=\"https:\/\/www.delveinsight.com\/report-store\/atopic-dermatitis-market\">atopic dermatitis<\/a>, and APG273, a combination of <strong>zumilokibart and APG333<\/strong>, an anti-TSLP half-life\u2013extended monoclonal antibody, currently under development for asthma.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-truelab-and-bionyra-enter-strategic-licensing-agreement-for-monoclonal-and-bispecific-antibody-assets\"><span class=\"ez-toc-section\" id=\"TrueLab_and_Bionyra_Enter_Strategic_Licensing_Agreement_for_Monoclonal_and_Bispecific_Antibody_Assets\"><\/span>TrueLab and Bionyra Enter Strategic Licensing Agreement for Monoclonal and Bispecific Antibody Assets<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>TrueLab Biopharmaceutical<\/strong>, an immunology-focused biotechnology company utilizing a proprietary AI-enabled research and development platform to create innovative treatments for immune-mediated inflammatory disorders, has announced an exclusive licensing agreement with <strong>Bionyra Pharma<\/strong>. The deal covers two of TrueLab\u2019s assets: <strong>TL-001<\/strong>, an anti-TL1A monoclonal antibody, and <strong>TL-003<\/strong>, a TL1A \u00d7 IL-23p19 <a href=\"https:\/\/www.delveinsight.com\/report-store\/bispecific-antibody-competitive-landscape\">bispecific antibody<\/a>.<\/p>\n\n\n\n<p>Under the agreement, Bionyra receives exclusive global rights, excluding Greater China, to research, develop, manufacture, and commercialize both candidates. In return, TrueLab may receive up to $985 million in potential payments, including upfront consideration and development, regulatory, and commercial milestones, along with tiered royalties on future net sales. The company will also obtain a single-digit equity stake in Bionyra upon the completion of the latter\u2019s Series A financing round.<\/p>\n\n\n\n<p>The partnership additionally gives Bionyra the option to further develop other preclinical assets from TrueLab under a similar licensing structure. As part of the transaction, Bionyra has closed a <strong>$165 million<\/strong> Series A financing round co-led by Jeito Capital and Sofinnova Partners, with participation from Arkin Capital, Sanofi Ventures, Sixty Degree Capital, Vives Partners, and Apollo Health Ventures.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-nura-bio-secures-73-8m-series-b-to-accelerate-sarm1-inhibitor-development\"><span class=\"ez-toc-section\" id=\"Nura_Bio_Secures_738M_Series_B_to_Accelerate_SARM1_Inhibitor_Development\"><\/span>Nura Bio Secures $73.8M Series B to Accelerate SARM1 Inhibitor Development<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Nura Bio Inc.<\/strong> has secured <strong>$73.8 million <\/strong>in Series B financing and announced progress across its two clinical-stage SARM1 inhibitor programs. The funding round was led by The Column Group, with participation from Euclidean Capital, Samsara BioCapital, and Sanofi Ventures. The proceeds will support the advancement of Nura Bio\u2019s clinical pipeline, including the ongoing <strong>Phase 1b\/2a trial of NB-4746<\/strong>, an orally administered, brain-penetrant <strong>SARM1 inhibitor<\/strong> that has recently begun dosing patients with <a href=\"https:\/\/www.delveinsight.com\/report-store\/amyotrophic-lateral-sclerosis-als-market\">amyotrophic lateral sclerosis (ALS)<\/a>.<\/p>\n\n\n\n<p><em>\u201cALS remains a devastating neurodegenerative disorder with limited treatment options and no cure,\u201d said Prof. Jeremy Shefner, MD, PhD, Professor of Neurology at Barrow Neurological Institute and neurologist at the Gregory W. Fulton ALS &amp; Neuromuscular Disease Center. \u201cNura Bio has pioneered the development of neuroprotective therapies targeting SARM1, a key driver of axonal degeneration. Advancing this program marks a significant step toward evaluating the therapeutic potential of SARM1 inhibition in ALS.\u201d<\/em><\/p>\n\n\n\n<p>NB-4746 is designed to block SARM1-mediated axonal degeneration and has demonstrated neuroprotective effects in multiple preclinical models of nerve injury and neurodegenerative diseases, including ALS. In a Phase 1 study involving healthy volunteers, the candidate exhibited a favorable safety and tolerability profile while achieving targeted exposure levels in both plasma and cerebrospinal fluid.<\/p>\n\n\n\n<p>In parallel, Nura Bio has initiated dosing in a first-in-human study of NB-9402, an oral covalent allosteric SARM1 inhibitor. The candidate has shown potent activity and durable efficacy in preclinical models of neurological disorders, further strengthening the company\u2019s leadership in the development of SARM1-targeted therapies.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-moderna-s-mrna-1010-wins-unanimous-fda-advisory-committee-support\"><span class=\"ez-toc-section\" id=\"Modernas_mRNA-1010_Wins_Unanimous_FDA_Advisory_Committee_Support\"><\/span>Moderna&#8217;s mRNA-1010 Wins Unanimous FDA Advisory Committee Support<span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p><strong>Moderna, Inc.<\/strong> announced that the FDA\u2019s Vaccines and Related Biological Products Advisory Committee (VRBPAC) unanimously voted (9-0) that the benefits of <strong>mRNA-1010<\/strong>, the company&#8217;s investigational <a href=\"https:\/\/www.delveinsight.com\/report-store\/seasonal-influenza-market\">seasonal influenza vaccine<\/a>, outweigh its risks for preventing influenza in adults aged 50\u201364 years, as well as in individuals aged 65 years and older.<\/p>\n\n\n\n<p><em>&#8220;We are grateful for the comprehensive evaluation conducted by VRBPAC and for its acknowledgment of the clinical data supporting mRNA-1010,&#8221; said St\u00e9phane Bancel, Chief Executive Officer of Moderna. &#8220;Seasonal influenza continues to place a considerable health burden on older adults, leading to significant illness and hospitalizations each year. We believe mRNA-1010 could offer a valuable new preventive option and further highlight the adaptability of our mRNA technology platform. We look forward to continued engagement with the FDA throughout the review process.&#8221;<\/em><\/p>\n\n\n\n<p>Data reviewed by VRBPAC included findings from Moderna&#8217;s Phase 3 clinical development program, notably the primary analysis from the pivotal <strong>Phase 3 study (NCT06602024)<\/strong>. These results, first reported in June 2025 and subsequently published in The New England Journal of Medicine, reinforce the vaccine&#8217;s potential as a differentiated, non-egg-based influenza prevention option for older adults.<\/p>\n\n\n\n<p>The safety findings observed across the Phase 3 program were consistent with those reported in earlier studies of Moderna&#8217;s influenza vaccine candidate. As part of its ongoing evaluation of Moderna&#8217;s Biologics License Application (BLA) for mRNA-1010, the FDA will consider VRBPAC&#8217;s recommendations. However, advisory committee recommendations are not binding, and the FDA retains sole authority over the final approval decision.<\/p>\n\n\n\n<p>mRNA-1010 is currently under regulatory review in the United States, the European Union, Canada, and Australia. Moderna has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 5, 2026, by the FDA. The company also plans to expand regulatory filings to additional countries throughout 2026.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Definium Therapeutics Advances DT120 ODT with Positive Results from Pivotal Phase 3 EMERGE Study Definium Therapeutics, Inc. reported positive topline findings from Emerge, its first Phase 3 randomized, double-blind, placebo-controlled trial assessing a single 100 \u00b5g dose of DT120 (lysergide) orally disintegrating tablet (ODT) in adults with major depressive disorder (MDD). The study successfully achieved [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":35511,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[74,7478,349,16942,639,23022],"industry":[17225],"therapeutic_areas":[17237,17245],"class_list":["post-35510","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-amyotrophic-lateral-sclerosis","tag-atopic-dermatitis","tag-latest-pharma-news","tag-major-depressive-disorder","tag-pharma-news","tag-seasonal-influenza","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-neurology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Pharma News | Definium Therapeutics, AbbVie, Apogee<\/title>\n<meta name=\"description\" content=\"Definium\u2019s DT120; AbbVie\u2019s Apogee Acquisition; TrueLab and Bionyra Collaboration; Nura Bio\u2019s Series B Financing; Moderna\u2019s mRNA-1010\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharma News | Definium Therapeutics, AbbVie, Apogee\" \/>\n<meta property=\"og:description\" content=\"Definium\u2019s DT120; AbbVie\u2019s Apogee Acquisition; TrueLab and Bionyra Collaboration; Nura Bio\u2019s Series B Financing; Moderna\u2019s mRNA-1010\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-23T11:57:06+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-23T11:57:07+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/pharma-news-for-definium-abbvie-apogee.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"772\" \/>\n\t<meta property=\"og:image:height\" content=\"482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pharma News | Definium Therapeutics, AbbVie, Apogee","description":"Definium\u2019s DT120; AbbVie\u2019s Apogee Acquisition; TrueLab and Bionyra Collaboration; Nura Bio\u2019s Series B Financing; Moderna\u2019s mRNA-1010","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee","og_locale":"en_US","og_type":"article","og_title":"Pharma News | Definium Therapeutics, AbbVie, Apogee","og_description":"Definium\u2019s DT120; AbbVie\u2019s Apogee Acquisition; TrueLab and Bionyra Collaboration; Nura Bio\u2019s Series B Financing; Moderna\u2019s mRNA-1010","og_url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2026-06-23T11:57:06+00:00","article_modified_time":"2026-06-23T11:57:07+00:00","og_image":[{"width":772,"height":482,"url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/pharma-news-for-definium-abbvie-apogee.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee","url":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee","name":"Pharma News | Definium Therapeutics, AbbVie, Apogee","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee#primaryimage"},"thumbnailUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/pharma-news-for-definium-abbvie-apogee.webp","datePublished":"2026-06-23T11:57:06+00:00","dateModified":"2026-06-23T11:57:07+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Definium\u2019s DT120; AbbVie\u2019s Apogee Acquisition; TrueLab and Bionyra Collaboration; Nura Bio\u2019s Series B Financing; Moderna\u2019s mRNA-1010","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/pharma-news-for-definium-abbvie-apogee#primaryimage","url":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/pharma-news-for-definium-abbvie-apogee.webp","contentUrl":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/pharma-news-for-definium-abbvie-apogee.webp","width":772,"height":482,"caption":"pharma-news-for-definium-abbvie-apogee"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/www.delveinsight.com\/blog\/wp-content\/uploads\/2026\/06\/pharma-news-for-definium-abbvie-apogee-300x187.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">amyotrophic lateral sclerosis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Atopic dermatitis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Major Depressive Disorder<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">seasonal influenza<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">amyotrophic lateral sclerosis<\/span>","<span class=\"advgb-post-tax-term\">Atopic dermatitis<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">Major Depressive Disorder<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">seasonal influenza<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 3 hours ago","modified":"Updated 3 hours ago"},"absolute_dates":{"created":"Posted on Jun 23, 2026","modified":"Updated on Jun 23, 2026"},"absolute_dates_time":{"created":"Posted on Jun 23, 2026 5:27 pm","modified":"Updated on Jun 23, 2026 5:27 pm"},"featured_img_caption":"pharma-news-for-definium-abbvie-apogee","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35510","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=35510"}],"version-history":[{"count":1,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35510\/revisions"}],"predecessor-version":[{"id":35512,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/35510\/revisions\/35512"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/35511"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=35510"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=35510"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=35510"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=35510"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=35510"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}